TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis

By sjmartinez • January 24, 2023

Ganz T, Nemeth E, Rivella S, Goldberg P, Dibble AR, McCaleb ML, Guo S, Monia BP, Barrett TD. TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis. Adv Ther. 2023 Jan 23. doi: 10.1007/s12325-022-02421-w. Epub ahead of print. PMID: 36690839.

Tags: Hematology/Oncology, Hemochromatosis, Ineffective erythropoiesis, iron overload, Iron restriction, Publications, Pulmonary, Critical Care & Sleep Medicine

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu[...]

The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need to Know

Graham DM, Lofftus S, Azizi L, Berkowitz MJ, Teshome M. The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need[...]

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial

Wainberg ZA, Lee KW, Kim JG, Devoe C, Strickler JH, Baum J, Jia C, Kagey MH, Sirard CA, Stein A, Scott AJ, Pelster M, Moehler[...]